![Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study | Annals of the Rheumatic Diseases Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study | Annals of the Rheumatic Diseases](https://ard.bmj.com/content/annrheumdis/68/6/805/F2.large.jpg)
Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study | Annals of the Rheumatic Diseases
![958-09-8 | 2'-Deoxyadenosine | 167: PN: US20040053876 SEQID: 167 unclaimed DNA; 9-(2-Deoxy-β-D-erythro-pentofuranosyl)adenine; NSC 141848; NSC 143510; NSC 83258; 1-(6-Amino-9H-purin-9-yl)-1,2-dideoxy-β-D-ribofuranose; | C₁₀H₁₃N₅O₃ | TRC 958-09-8 | 2'-Deoxyadenosine | 167: PN: US20040053876 SEQID: 167 unclaimed DNA; 9-(2-Deoxy-β-D-erythro-pentofuranosyl)adenine; NSC 141848; NSC 143510; NSC 83258; 1-(6-Amino-9H-purin-9-yl)-1,2-dideoxy-β-D-ribofuranose; | C₁₀H₁₃N₅O₃ | TRC](https://www.trc-canada.com/prod-img/D239583.png)
958-09-8 | 2'-Deoxyadenosine | 167: PN: US20040053876 SEQID: 167 unclaimed DNA; 9-(2-Deoxy-β-D-erythro-pentofuranosyl)adenine; NSC 141848; NSC 143510; NSC 83258; 1-(6-Amino-9H-purin-9-yl)-1,2-dideoxy-β-D-ribofuranose; | C₁₀H₁₃N₅O₃ | TRC
![IJMS | Free Full-Text | Experimental Studies on the Thermal Properties and Decomposition Course of a Novel Class of Heterocyclic Anticancer Drug Candidates IJMS | Free Full-Text | Experimental Studies on the Thermal Properties and Decomposition Course of a Novel Class of Heterocyclic Anticancer Drug Candidates](https://pub.mdpi-res.com/ijms/ijms-24-06190/article_deploy/html/images/ijms-24-06190-g001-550.jpg?1679889205)
IJMS | Free Full-Text | Experimental Studies on the Thermal Properties and Decomposition Course of a Novel Class of Heterocyclic Anticancer Drug Candidates
![Encoded Library Technology as a Source of Hits for the Discovery and Lead Optimization of a Potent and Selective Class of Bactericidal Direct Inhibitors of Mycobacterium tuberculosis InhA | Journal of Medicinal Encoded Library Technology as a Source of Hits for the Discovery and Lead Optimization of a Potent and Selective Class of Bactericidal Direct Inhibitors of Mycobacterium tuberculosis InhA | Journal of Medicinal](https://pubs.acs.org/cms/10.1021/jm401326j/asset/images/medium/jm-2013-01326j_0012.gif)
Encoded Library Technology as a Source of Hits for the Discovery and Lead Optimization of a Potent and Selective Class of Bactericidal Direct Inhibitors of Mycobacterium tuberculosis InhA | Journal of Medicinal
![Libro monoclonal antibody introduction: ipilimumab, certolizumab pegol, matuzumab, ofatumumab, otelixizumab, glembatumumab vedotin, source wikipedia, ISBN 9781157410058. Comprar en Buscalibre Libro monoclonal antibody introduction: ipilimumab, certolizumab pegol, matuzumab, ofatumumab, otelixizumab, glembatumumab vedotin, source wikipedia, ISBN 9781157410058. Comprar en Buscalibre](https://images.cdn1.buscalibre.com/fit-in/360x360/b8/2a/f276117eebcada00bde673f1dac6fce0.jpg)
Libro monoclonal antibody introduction: ipilimumab, certolizumab pegol, matuzumab, ofatumumab, otelixizumab, glembatumumab vedotin, source wikipedia, ISBN 9781157410058. Comprar en Buscalibre
![Phthalazinone Pyrazoles as Potent, Selective, and Orally Bioavailable Inhibitors of Aurora-A Kinase | Journal of Medicinal Chemistry Phthalazinone Pyrazoles as Potent, Selective, and Orally Bioavailable Inhibitors of Aurora-A Kinase | Journal of Medicinal Chemistry](https://pubs.acs.org/cms/10.1021/jm101346r/asset/images/medium/jm-2010-01346r_0007.gif)